

CITATION REPORT

List of articles citing

SGLT-2 inhibitors: Their pleiotropic properties

DOI: 10.1016/j.dsx.2016.12.003

Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, 311-315.

Source: <https://exaly.com/paper-pdf/66718217/citation-report.pdf>

Version: 2024-04-04

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
15	SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE. <i>Journal of Biological Chemistry</i> , 2017 , 292, 5335-5348	5.4	157
14	Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION). <i>Endocrine Journal</i> , 2018 , 65, 859-867	2.9	17
13	Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis. <i>Clinical Therapeutics</i> , 2019 , 41, 322-334.e11	3.5	16
12	Diabetic Pharmacotherapies in Kidney Disease. 2019 , 49-74		
11	Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?. <i>Metabolism: Clinical and Experimental</i> , 2019 , 96, vi-xi	12.7	4
10	Pharmacotherapy of obesity: Available medications and drugs under investigation. <i>Metabolism: Clinical and Experimental</i> , 2019 , 92, 170-192	12.7	98
9	Canagliflozin impedes ischemic hind-limb recovery in the setting of diabetes. <i>Vascular Medicine</i> , 2021 , 26, 131-138	3.3	2
8	Insulin Therapy Is Associated With an Increased Risk of Carotid Plaque in Type 2 Diabetes: A Real-World Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 599545	5.4	2
7	Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?. <i>Cardiology</i> , 2021 , 146, 201-206	1.6	4
6	Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats. <i>American Journal of Physiology - Renal Physiology</i> , 2021 , 320, F761-F771	4.3	9
5	Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 1253-1267	3.9	2
4	INFLUENCE OF EMPAGLIFLOZIN ON THE KIDNEYS IN NORMOGLYCEMIC RATS WITH HEART FAILURE. <i>Nephrology (Saint-Petersburg)</i> , 2017 , 21, 83-92	0.4	
3	MECHANISMS AND CLINICAL SIGNIFICANCE OF NEPHROPROTECTIVE ACTION OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS. <i>Juvenis Scientia</i> , 2019 , 4-9	0.1	
2	New Therapeutic Agents in Obesity-Related Cardiovascular Disorders: Molecular and Cellular Insights. 2021 , 313-335		0
1	Amelioration of murine diabetic nephropathy with a SGLT2 inhibitor is associated with suppressing abnormal expression of hypoxia-inducible factors.. <i>American Journal of Pathology</i> , 2022 ,	5.8	0